Zentynel

zentynel.com

VCMatch tracks Zentynel as an investor focused on Biotech, Healthtech, and Digital Health companies, Pre-Seed and Seed rounds, Latin America, Americas, and Chile markets, and $1m to $2m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$1m to $2m

Stages

Pre-Seed, Seed, Series A

Focus Areas

Biotech, Healthtech, Digital Health

Geography

Latin America, Americas, and Chile

Investment Thesis

Zentynel believes biotech is fundamental to the next industrial revolution and that Latin America possesses unique advantages—world-class scientific talent, unparalleled biodiversity, cost-effective R&D, and growing entrepreneurial capacity—to become a global biotech leader. They combine capital, scientific depth, and operational expertise to help founders transform breakthrough science into scalable businesses with both financial returns and measurable real-world impact.

Is Zentynel right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Zentynel is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Healthtech, Digital Health, and Medtech, especially across Latin America, Americas, and Chile, with public check-size signals around $1m to $2m.

Focus statement

Zentynel invests across the entire biotech value chain with a One Health perspective, focusing on early-stage companies with global ambition and strong Latin American roots in human/animal health, digital health/AI platforms, and agritech/food/environmental biotech solutions.

Value Add

Latin America's first specialized biotech venture capital fund
One Health approach integrating human, animal, and environmental health interconnection
Active investors providing direct operational support, international networks, and strategic advisory
BioGratitud philosophy: support entrepreneurs even outside direct portfolio to strengthen ecosystem
Team combines 40+ years of biotech industry experience (co-founder of Chiron, Hepatitis B vaccine developer) with regulatory expertise and scientific depth
Invested across 6 countries demonstrating regional reach and ecosystem understanding
25-30% of fund reserved for follow-on investments showing commitment to portfolio companies